ArticleJournal of nanobiotechnology2026
Alkali-controlled one-pot synthesis of ultrasmall PEGylated polydopamine nanoparticles for diverse biological applications.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polysaccharide-Modified Gold Nanorod and Polydopamine Nanocarriers for Near-Infrared Light-Responsive Biomedical Applications: A Comparative Review.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPolydopamine nanoparticles (PDA NPs) hold considerable significance in biomedical field due to their diverse multifunctionality, including efficient metal ion chelation, intrinsic antioxidant activity, and robust photothermal properties. Especially, ultrasmall PDA NPs can evade rapid liver and spleen accumulation, enabling multi-organ distribution and wide biological applications. However, current methods for synthesizing ultrasmall PDA NPs face the bottleneck of complex synthesis processes.
methodsWe showed an alkali-controlled one-pot synthesis of ultrasmall PEGylated PDA (UPPDA) NPs. Upon Mn
resultsPPMn NPs enable precise diagnosis of glioma, carotid artery stenosis, and acute kidney injury through MRI. Additionally, UPPDA and PPMn NPs exhibit outstanding antioxidant properties and demonstrate effective photothermal ablation capabilities at the cellular level.
conclusionsThe proposed UPPDA NPs provide a universal platform for the diagnosis and treatment of various diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.